Updated:
Ambria Capital
Ambria Capital is an early-stage investment firm focused on psychedelics, digital health, cryptocurrency, and cybersecurity.
Ambria Capital
Ambria Capital is a Brooklyn-based investment firm that targets early-stage companies in the mental health and technology spaces. The firm's website does not disclose founding year, principals, or wealth origin. Ambria's strategy focuses on four verticals: psychedelics, digital health, cryptocurrency, and cybersecurity. The firm backs startups in psychedelic-assisted therapies, citing FDA breakthrough designations and growing capital investment in the sector. Its portfolio includes Wesana Health, a company developing psychedelic-based treatments, as disclosed on its website. Geographically, Ambria lists offices in Brooklyn, Zurich, San Juan, Lewes, and Highland Park, suggesting a North American and European footprint. No team size, AUM, or deployment figures are published. No recent operational events could be verified from public sources. A structural differentiator is Ambria's narrow thematic focus on the intersection of mental health and frontier technologies, particularly psychedelics. This positions it in a niche segment of early-stage investing tied to regulatory and clinical milestones.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Brooklyn
Corporate office
Brooklyn, United States
Additional offices
Zurich, Switzerland · San Juan, Puerto Rico · Lewes, DE, United States · Highland Park, IL, United States
Sector focus
Frequently asked questions
Who runs investment decisions at Ambria Capital?
Ambria Capital does not publicly name its investment principals. The firm's website, LinkedIn presence, or public filings do not list a founder, CEO, CIO, or managing partners. Institutional allocators seeking governance clarity will find no disclosed decision-making structure.
What investment stages does Ambria Capital target?
Based on its website, Ambria focuses on early-stage companies in mental health and technology. The firm describes itself as empowering early-stage ventures, but does not specify whether it primarily does seed, Series A, or later rounds. Its portfolio includes Wesana Health, which suggests some growth-stage exposure.
Which sectors does Ambria Capital specialize in?
Ambria lists four sector focuses on its website: psychedelics, digital health, cryptocurrency, and cybersecurity. The firm's clearest emphasis is on psychedelic-assisted therapies for mental health, which it calls a "massive market opportunity" driven by FDA breakthrough designations and clinical trial success (per its website).
Does Ambria Capital offer fund commitments or only direct investments?
Ambria's website does not specify whether it makes fund commitments, direct investments, or a mix. The firm describes itself as investing in early-stage companies, and its one named portfolio company — Wesana Health — suggests direct equity positions. No fund vehicles or SPVs are disclosed.
Is Ambria Capital a single family office or a venture firm?
Ambria Capital does not publicly define its structure. Its website lacks the language typical of single or multi-family offices. Based on public information, it appears to operate as a thematic venture capital investor rather than a family office, but no definitive classification is possible from available sources.
Where does the underlying wealth at Ambria Capital come from?
Ambria Capital does not disclose the origin of its capital. No public information links it to a specific family fortune, founder background, or institutional endowment. The firm's wealth base remains unknown.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: